Should HIV patients start drugs immediately?

A new government-funded study suggests that patients with HIV may have less risk of dying if they begin HAART, or highly active antiretroviral therapy, sooner than current guidelines currently recommend. So will the NIH fight for new guidelines to get patients on meds sooner? Report

Suggested Articles

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.